Control released permeation bump tablet of venlafaxine hydrochloride and its prepn process

A technology of venlafaxine hydrochloride and osmotic pump controlled release, applied in pharmaceutical formulations, medical preparations containing active ingredients, drug delivery, etc. problems, to achieve the effect of small fluctuation, small gastrointestinal side effects, and stable blood drug concentration

Inactive Publication Date: 2006-10-18
潘卫三 +2
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although sustained-release preparations have solved the problem of frequent dosing of the above-mentioned common preparations (only need to take medicine once a day), they can also reduce gastrointestinal side effects to a certain extent; The release and absorption rate of the drug is also affected by factors such as gastric juice or intestinal juice in the patient's body, which is difficult to control and predict, so its blood drug concentration may still fluctuate greatly, with certain instability, and its effective duration and gastrointestinal tract The magnitude of side effects also varies from person to person, and individual differences have a greater impact and are uncontrollable
Patients also often have poor compliance due to frequent medication or severe side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Control released permeation bump tablet of venlafaxine hydrochloride and its prepn process
  • Control released permeation bump tablet of venlafaxine hydrochloride and its prepn process

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] The venlafaxine hydrochloride osmotic pump controlled-release tablet preparation with a weight ratio of drug tablet core and semipermeable film coating of 1:0.035, wherein:

[0027] The composition of the drug tablet core is: 75 parts of venlafaxine hydrochloride, 114 parts of microcrystalline cellulose, 4 parts of sodium chloride, 6 parts of povidone K30 and 1 part of magnesium stearate.

[0028] The composition of the semipermeable film coating was: 9 parts of cellulose acetate, 0.78 parts of diethyl phthalate and 0.22 parts of polyethylene glycol 1500.

[0029] The preparation method of the above-mentioned venlafaxine hydrochloride osmotic pump controlled-release tablet preparation comprises the following steps:

[0030] (1) Preparation of drug tablet core: get the venlafaxine hydrochloride, microcrystalline cellulose, sodium chloride and povidone K30 of the proportioning, mix well, add 95% ethanol solution to make soft material in right amount, pass 20 Mesh sieve g...

Embodiment 2

[0035] The venlafaxine hydrochloride osmotic pump controlled-release tablet preparation in which the weight ratio of the drug tablet core and the semipermeable film coating is 1:0.05, wherein:

[0036] The composition of the drug tablet core is: 75 parts of venlafaxine hydrochloride, 120 parts of microcrystalline cellulose, 1 part of sodium chloride, 15 parts of povidone K30 and 0.1 part of magnesium stearate.

[0037] The composition of the semipermeable film coating was: 6 parts of cellulose acetate, 0.9 part of diethyl phthalate and 0.1 part of polyethylene glycol 1500.

[0038] The preparation method of the above-mentioned venlafaxine hydrochloride osmotic pump controlled-release tablet preparation comprises the following steps:

[0039] (1) Preparation of drug tablet core: get the venlafaxine hydrochloride, microcrystalline cellulose, sodium chloride and povidone K30 of the proportioning, mix well, add 90% ethanol solution to make soft material in right amount, pass 20 M...

Embodiment 3

[0044] The venlafaxine hydrochloride osmotic pump controlled-release tablet preparation in which the weight ratio of the drug tablet core and the semipermeable film coating is 1:0.02, wherein:

[0045] The composition of the drug tablet core is: 75 parts of venlafaxine hydrochloride, 100 parts of microcrystalline cellulose, 30 parts of sodium chloride, 1 part of povidone K30 and 10 parts of magnesium stearate.

[0046] The composition of the semipermeable film coating was: 12 parts of cellulose acetate, 0.6 part of diethyl phthalate and 0.4 part of polyethylene glycol 1500.

[0047] The preparation method of the above-mentioned venlafaxine hydrochloride osmotic pump controlled-release tablet preparation comprises the following steps:

[0048] (1) Preparation of drug tablet core: get the venlafaxine hydrochloride, microcrystalline cellulose, sodium chloride and povidone K30 of the proportioning, mix well, add 95% ethanol solution to make soft material in right amount, pass 20 ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The present invention discloses one kind of osmotic pump controlled release tablet of venlafaxine hydrochloride. The tablet consists of medicine core of venlafaxine hydrochloride and semipermeable film coating with small holes. The medicine core consists of venlafaxine hydrochloride in 75 weight portions, stuffing in 30-250 weight portions, osmotic pressure promoter in 1-50 weight portions, adhesive in 1-20 weight portions and lubricant in 0.1-20 weight portions. The semipermeable film coating consists of semipermeable film coating material in 5-15 weight portions and plasticizer in 1 weight portion. The tablet has excellent release controlling effect, high safety and good patient dependence. The present invention also discloses the preparation process of the osmotic pump controlled release tablet of venlafaxine hydrochloride.

Description

technical field [0001] The invention relates to the field of pharmaceutical preparations, in particular to a novel antidepressant venlafaxine hydrochloride osmotic pump controlled-release tablet preparation and a preparation method for the osmotic pump controlled-release tablet preparation. Background technique [0002] Venlafaxine is a new type of antidepressant, which has the remarkable characteristics of quick effect (4 days to 1 week), good tolerance, and good short-term and long-term therapeutic effects. At present, the venlafaxine preparations that have been marketed or reported at home and abroad include ordinary preparations and sustained-release preparations of different specifications, such as ordinary capsules, sustained-release tablets, sustained-release capsules and sustained-release pellets. However, venlafaxine in common preparations has problems such as short half-life (about 5±2 hours), frequent administration (2-3 times a day), and relatively large side eff...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/137A61K9/22A61P25/24
Inventor 潘卫三李威欧阳德方
Owner 潘卫三
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap